

Author Index

A

- Adler, L.E., and Waldo, M.C. Counterpoint: A sensory gating—hippocampal model of schizophrenia, 17(1):19-24, 1991.
- Amador, X.F.; Strauss, D.H.; Yale, S.A.; and Gorman, J.M. Awareness of illness in schizophrenia, 17(1):113-132, 1991.
- an der Heiden, W.; see Häfner, H.
- Andreasen, N.C. Assessment issues and the cost of schizophrenia, 17(3):475-481, 1991; Reply to "Phenomenology or physicalism?," 17(2):187-189, 1991; Schizophrenia and related disorders in *DSM-IV*: Editor's introduction, 17(1):25-26, 1991; see also Flaum, M.
- Andreasen, N.C., and Flaum, M. Schizophrenia: The characteristic symptoms, 17(1):27-49, 1991.
- Andrews, G. The cost of schizophrenia revisited, 17(3):389-394, 1991.
- Angermeyer, M.C.; Kühn, L.; and Goldstein, J.M. Gender and the course of schizophrenia: Differences in treated outcomes, 16(2):293-307, 1990.
- Anonymous. First person account: A pit of confusion, 16(2):355-359, 1990; First person account: Behind the mask: A functional schizophrenic copes, 16(3):547-549, 1990; First person account: Birds of a psychic feather, 16(1):165-168, 1990.
- Appelbaum, P.S.; see Cassens, G.
- Aravagiri, M.; see Van Putten, T.

B

- Bardenstein, K.K.; see McGlashan, T.H.
- Bartels, S.J.; Drake, R.E.; Wallach, M.A.; and Freeman, D.H. Characteristic hostility in schizophrenic outpatients, 17(1):163-171, 1991.
- Bartko, J.J. Measurement and reliability: Statistical thinking considerations, 17(3):483-489, 1991.

- Bassett, A.; see Weeks, D.E.
- Battaglia, M.; Gasperini, M.; Sciuto, G.; Scherillo, P.; Diaferia, G.; and Bellodi, L. Psychiatric disorders in the families of schizotypal subjects, 17(4):659-668, 1991.
- Beaudett, M.S.; see Drake, R.E.
- Beecham, J.; Knapp, M.; and Fenyo, A. Costs, needs, and outcomes, 17(3):427-439, 1991.
- Bellack, A.S.; see Mueser, K.T.
- Bellodi, L.; see Battaglia, M.
- Benes, F.M.; Sorensen, I.; and Bird, E.D. Reduced neuronal size in posterior hippocampus of schizophrenic patients, 17(4):597-608, 1991.
- Benson, D.F., and Stuss, D.T. Frontal lobe influences on delusions: A clinical perspective, 16(3):403-411, 1990.
- Bird, E.D.; see Benes, F.M.
- Blaska, B. First person account: What it is like to be treated like a CMI, 17(1):173-176, 1991.
- Bleuler, M. Seasonality of birth of future schizophrenics and seasonality of depressive episodes (Letter to the Editor), 17(2):191-192, 1991.
- Bowers, M.B., Jr.; see Lieberman, J.A.
- Bowers, M.B., Jr.; Mazure, C.M.; Nelson, J.C.; and Jatlow, P.I. Psychotogenic drug use and neuroleptic response, 16(1):81-85, 1990.
- Bowler, A.E.; see Torrey, E.F.
- Bracha, H.S. Etiology of structural asymmetry in schizophrenia: An alternative hypothesis (Letter to the Editor), 17(4):551-553, 1991.
- Braff, D.L.; see Butler, R.W.
- Brenner, H.D.; Dencker, S.J.; Goldstein, M.J.; Hubbard, J.W.; Keegan, D.L.; Kruger, G.; Kulhanek, F.; Liberman, R.P.; Malm, U.; and Midha, K.K. Defining treatment refractoriness in schizophrenia, 16(4):551-561, 1990.
- Brown, C.H.; see Pulver, A.E.
- Brzustowicz, L.; see Weeks, D.E.

- Buchsbaum, M.S. Frontal lobes, basal ganglia, temporal lobes—Three sites for schizophrenia?, 16(3):377-378, 1990; The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia, 16(3):379-389, 1990.
- Burke, S.S.; see Test, M.A.
- Burns, T., and Raftery, J. Cost of schizophrenia in a randomized trial of home-based treatment, 17(3):407-410, 1991.
- Butler, R.W., and Braff, D.L. Delusions: A review and integration, 17(4):633-647, 1991.
- C**
- Caldwell, C.B., and Gottesman, I.I. Schizophrenics kill themselves too: A review of risk factors for suicide, 16(4):571-589, 1990.
- Caldwell-Smith, G. First person account: A mother's view, 16(4):687-690, 1990.
- Capri, S.; see Moscarelli, M.
- Carlsson, A.; see Carlsson, M.
- Carlsson, M., and Carlsson, A. Schizophrenia: A subcortical neurotransmitter imbalance syndrome?, 16(3):425-432, 1990.
- Cassens, G.; Inglis, A.K.; Appelbaum, P.S.; and Gutheil, T.G. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients, 16(3):477-499, 1990.
- Centifanti, J.B.; see Rogers, J.A.
- Chabert, N.; see Van Putten, T.
- Childers, S.E., and Harding, C.M. Gender, premorbid social functioning, and long-term outcome in DSM-III schizophrenia, 16(2):309-318, 1990.
- Christison, G.W.; Kirch, D.G.; and Wyatt, R.J. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia, 17(2):217-245, 1991.
- Clark, C.; see Kopala, L.
- Clarkin, J.F.; see Haas, G.L.
- Coffman, J.A.; see Nasrallah, H.A.
- Copolov, D.L.; see McGorry, P.D.
- Cornblatt, B.; see Weeks, D.E.
- Costa, J.; see Jin, Y.
- Crow, T.J. Temporal lobe asymmetries as the key to the etiology of schizophrenia, 16(3):433-443, 1990.
- D**
- Dalén, P. Does age incidence explain all season-of-birth effects in the literature?, 16(1):11-12, 1990; Is the familial/sporadic subdivision a method of genetics?, 16(3):363-365, 1990.
- de Girolamo, G.; see Sartorius, N.
- Dencker, S.J.; see Brenner, H.D.
- Diaferia, G.; see Battaglia, M.
- Dixon, L.; Haas, G.; Weiden, P.; Sweeney, J.; and Frances, A. Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients' self-reports, 16(1):69-79, 1990.
- Dobscha, S.K.; see Hoffman, R.E.
- Docherty, N.M.; see Harvey, P.D.
- Dossetor, C.R.; see McGorry, P.D.
- Douglas, M.S.; see Mueser, K.T.
- Drake, R.E.; see Bartels, S.J.
- Drake, R.E.; Osher, F.C.; Noordsy, D.L.; Hurlbut, S.C.; Teague, G.B.; and Beaudett, M.S. Diagnosis of alcohol use disorders in schizophrenia, 16(1):57-67, 1990.
- Dworkin, R.H.; see Lenzenweger, M.F.
- Dykman, R.A.; see Karson, C.N.
- E**
- Erlenmeyer-Kimling, L.; see Weeks, D.E.
- F**
- Farmer, A.; McGuffin, P.; and Gottesman, I.I. Problems and pitfalls of the family history positive and negative dichotomy: Response to Dalén, 16(3):367-370, 1990.
- Feinberg, I. Cortical pruning and the development of schizophrenia (Letter to the Editor), 16(4):567-568, 1990.
- Fenton, W.S.; see McGlashan, T.H.
- Fenyo, A.; see Beecham, J.
- Flaum, M.; see Andreasen, N.C.
- Flaum, M., and Andreasen, N.C. Diagnostic criteria for schizophrenia and related disorders: Options for DSM-IV, 17(1):133-156, 1991.
- Flor-Henry, P. Influence of gender in schizophrenia as related to other psychopathological syndromes, 16(2):211-227, 1990.
- Flowers, D.L.; see Wood, F.B.
- Fogg, L.; see Silverstein, M.L.
- Frances, A.; see Dixon, L.
- Freeman, D.H.; see Bartels, S.J.
- G**
- Gasperini, M.; see Battaglia, M.
- Gerlach, J. New antipsychotics: Classification, efficacy, and adverse effects, 17(2):289-309, 1991.
- Giel, R.; see Wiersma, D.
- Gilliam, T.C.; see Weeks, D.E.
- Glick, I.D.; see Haas, G.L.
- Goldberg, D. Cost-effectiveness studies in the treatment of schizophrenia: A review, 17(3):453-459, 1991.
- Goldman, H.H.; see Ridgely, M.S.
- Goldman-Rakic, P.S.; see Kirch, D.G.
- Goldstein, J.M.; see Angermeyer, M.C.
- Goldstein, J.M., and Tsuang, M.T. Gender and schizophrenia: An introduction and synthesis of findings, 16(2):179-183, 1990.
- Goldstein, J.M.; Santangelo, S.L.; Simpson, J.C.; and Tsuang, M.T. The role of gender in identifying subtypes of schizophrenia: A latent class analytic approach, 16(2):263-275, 1990.
- Goldstein, M.J.; see Brenner, H.D.
- Gorman, J.M.; see Amador, X.F.

- Gottesman, I.I.; *see* Caldwell, C.B.; Farmer, A.; Vinogradov, S.
- Green, M.F., and Kinsbourne, M. Subvocal activity and auditory hallucinations: Clues for behavioral treatments?, 16(4):617-625, 1990.
- Grove, W.M.; Lebow, B.S.; and Medus, C. Head size in relation to schizophrenia and schizotypy, 17(1):157-161, 1991.
- Gulley, L.R.; *see* Lewine, R.R.J.
- Gur, R.C.; *see* Gur, R.E.
- Gur, R.E., and Gur, R.C. Gender differences in regional cerebral blood flow, 16(2):247-254, 1990.
- Gur, R.E.; Gur, R.C.; and Saykin, A.J. Neurobehavioral studies in schizophrenia: Implications for regional brain dysfunction, 16(3):445-451, 1990.
- Gutheil, T.G.; *see* Cassens, G.
- ### H
- Haas, G.; *see* Dixon, L.
- Haas, G.L.; Glick, I.D.; Clarkin, J.F.; Spencer, J.H.; and Lewis, A.B. Gender and schizophrenia outcome: A clinical trial of an inpatient family intervention, 16(2):277-292, 1990.
- Häfner, H., and an der Heiden, W. Evaluating effectiveness and cost of community care for schizophrenic patients, 17(3):441-451, 1991.
- Harding, C.M.; *see* Childers, S.E.
- Harrison, G. Searching for the causes of schizophrenia: The role of migrant studies, 16(4):663-671, 1990.
- Harvey, P.D.; Docherty, N.M.; Serper, M.R.; and Rasmussen, M. Cognitive deficits and thought disorder: II. An 8-month followup study, 16(1):147-156, 1990.
- Heh, C.; *see* Jin, Y.
- Heritch, A.J. Evidence for reduced and dysregulated turnover of dopamine in schizophrenia, 16(4):605-615, 1990.
- Higenbottam, J.; *see* Koczapski, A.B.
- Hoffman, R.E., and Dobscha, S.K. Reduced cortico-cortical exchange of information as a possible etiology of schizophrenia—Reply to Feinberg (Letter to the Editor), 16(4):569-570, 1990.
- Holmes-Eber, P., and Riger, S. Hospitalization and the composition of mental patients' social networks, 16(1):157-164, 1990.
- Houpt, J.L.; *see* Lewine, R.R.J.
- Hu, T., and Jerrell, J. Cost-effectiveness of alternative approaches in treating severely mentally ill in California, 17(3):461-468, 1991.
- Hubbard, J.W.; *see* Brenner, H.D.
- Hurlbut, S.C.; *see* Drake, R.E.
- Hyde, A.P. Response to "Effects of caffeine on behavior of schizophrenic inpatients," 16(3):371-372, 1990.
- Hyland, B. First person account: A thousand cloudy days, 17(3):539-545, 1991.
- ### I
- Inglis, A.K.; *see* Cassens, G.
- Isenhardt, R.; *see* Jin, Y.
- ### J
- Jatlow, P.I.; *see* Bowers, M.B., Jr.
- Jerrell, J.; *see* Hu, T.
- Jewart, R.; *see* Lewine, R.R.J.
- Jin, Y.; Potkin, S.G.; Rice, D.; Sramek, J.; Costa, J.; Isenhardt, R.; Heh, C.; and Sandman, C.A. Abnormal EEG responses to photic stimulation in schizophrenic patients, 16(4):627-634, 1990.
- Johnson, M.M.; *see* Josiassen, R.C.
- Josiassen, R.C.; Roemer, R.A.; Johnson, M.M.; and Shagass, C. Are gender differences in schizophrenia reflected in brain event-related potentials?, 16(2):229-246, 1990.
- ### K
- Kane, J.M. New developments in the pharmacologic treatment of schizophrenia: Editor's introduction, 17(2):193-195, 1991; Obstacles to clinical research and new drug development in schizophrenia, 17(2):353-356, 1991; *see also* Safferman, A.; Szymanski, S.
- Kane, J.M., and Selzer, J. Considerations on "organic" exclusion criteria for schizophrenia, 17(1):69-73, 1991.
- Kaplan, I.; *see* McGorry, P.D.
- Karson, C.N.; Dykman, R.A.; and Paige, S.R. Blink rates in schizophrenia, 16(2):345-354, 1990.
- Kasten, A.M.; *see* Rosenson, M.K.
- Kay, S.R. Significance of the positive-negative distinction in schizophrenia, 16(4):635-652, 1990; *see also* Sandyk, R.
- Kay, S.R., and Sevy, S. Pyramidal model of schizophrenia, 16(3):537-545, 1990.
- Kee, K.; *see* Mueser, K.T.
- Keegan, D.L.; *see* Brenner, H.D.
- Keith, S.J., and Matthews, S.M. The diagnosis of schizophrenia: A review of onset and duration issues, 17(1):51-67, 1991.
- Kinon, B.J.; *see* Lieberman, J.A.; Safferman, A.
- Kinsbourne, M.; *see* Green, M.F.
- Kirch, D.G.; *see* Christison, G.W.
- Kirch, D.G.; Wagman, A.M.I.; and Goldman-Rakic, P.S. Commentary: The acquisition and use of human brain tissue in neuropsychiatric research, 17(4):593-596, 1991.
- Kluiter, H.; *see* Wiersma, D.
- Knapp, M.; *see* Beecham, J.
- Koczapski, A.B.; Ledwidge, B.; Paredes, J.; Kogan, C.; and Higenbottam, J. Multisubstance intoxication among schizophrenic inpatients: Reply to Hyde, 16(3):373-375, 1990.
- Kogan, C.; *see* Koczapski, A.B.
- Kopala, L., and Clark, C. Implications of olfactory agnosia for understanding sex differences in

- schizophrenia, 16(2):255-261, 1990.
- Kruger, G.; *see* Brenner, H.D.
- Kühn, L.; *see* Angermeyer, M.C.
- Kulhanek, F.; *see* Brenner, H.D.
- L**
- Lang, M.; *see* Seeman, M.V.
- Lebow, B.S.; *see* Grove, W.M.
- Ledwidge, B.; *see* Koczapski, A.B.
- Lehner, T.; *see* Weeks, D.E.
- Lenzenweger, M.F.; Dworkin, R.H.; and Wethington, E. Examining the underlying structure of schizophrenic phenomenology: Evidence for a three-process model, 17(3):515-524, 1991.
- Levinson, D.F., and Mowry, B.J. Defining the schizophrenia spectrum: Issues for genetic linkage studies, 17(3):491-514, 1991.
- Levinson, D.F.; *see* Mueser, K.T.
- Lewine, R.R.J. Reflections on Saugstad's "Social class, marriage, and fertility in schizophrenia," 16(2):171-174, 1990.
- Lewine, R.R.J.; Guley, L.R.; Risch, S.C.; Jewart, R.; and Houpt, J.L. Sexual dimorphism, brain morphology, and schizophrenia, 16(2):195-203, 1990.
- Lewis, A.B.; *see* Haas, G.L.
- Lewis, M.S. *Res ipsa loquitur*: The author replies, 16(1):17-28, 1990.
- Liberman, R.P.; *see* Brenner, H.D.
- Lieberman, J.A.; *see* Safferman, A.; Szymanski, S.
- Lieberman, J.A., and Bowers, M.B., Jr. Substance abuse comorbidity in schizophrenia: Editors' introduction, 16(1):29-30, 1990.
- Lieberman, J.A.; Kinon, B.J.; and Loebel, A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses, 16(1):97-110, 1990.
- Lim, K.O.; *see* Pfefferbaum, A.
- Loebel, A.D.; *see* Lieberman, J.A.
- M**
- Malm, U.; *see* Brenner, H.D.
- Marder, S.R.; *see* Van Putten, T.
- Marengo, J.T.; *see* Silverstein M.L.
- Matthews, S.M.; *see* Keith, S.J.
- Mazure, C.M.; *see* Bowers, M.B., Jr.
- McCulloch, P.B.; *see* Witelson, S.F.
- McGlashan, T.H., and Bardenstein, K.K. Gender differences in affective, schizoaffective, and schizophrenic disorders, 16(2):319-329, 1990.
- McGlashan, T.H., and Fenton, W.S. Classical subtypes for schizophrenia: Literature review for DSM-IV, 17(4):609-624, 1991.
- McGorry, P.D.; Copolov, D.L.; and Singh, B.S. Royal Park Multidiagnostic Instrument for Psychosis: Part I. Rationale and review, 16(3):501-515, 1990.
- McGorry, P.D.; Singh, B.S.; Copolov, D.L.; Kaplan, I.; Dossetor, C.R.; and van Riel, R.J. Royal Park Multidiagnostic Instrument for Psychosis: Part II. Development, reliability, and validity, 16(3):517-536, 1990.
- McGrath, J.A.; *see* Pulver, A.E.
- McGuffin, P.; *see* Farmer, A.
- McGuire, T.G. Measuring the economic costs of schizophrenia, 17(3):375-388, 1991.
- Medus, C.; *see* Grove, W.M.
- Meltzer, H.Y. Commentary: Defining treatment refractoriness in schizophrenia, 16(4):563-565, 1990; The mechanism of action of novel antipsychotic drugs, 17(2):263-287, 1991.
- Merskey, H. Sluggish schizophrenia (Letter to the Editor), 17(4):553, 1991.
- Mezzich, J.E. Architecture of clinical information and prediction of service utilization and cost, 17(3):469-474, 1991.
- Midha, K.K.; *see* Brenner, H.D.
- Moises, H.W.; *see* Vinogradov, S.
- Moorman, C.C.; *see* Pulver, A.E.
- Morrison, R.L.; *see* Mueser, K.T.
- Moscarelli, M., and Capri, S. The cost of schizophrenia: Editors' introduction, 17(3):367-373, 1991.
- Moscarelli, M.; Capri, S.; and Neri, L. Cost evaluation of chronic schizophrenic patients during the first 3 years after the first contact, 17(3):421-426, 1991.
- Mowry, B.J.; *see* Levinson, D.F.
- Mueser, K.T.; Douglas, M.S.; Bellack, A.S.; and Morrison, R.L. Assessment of enduring deficit and negative symptom subtypes in schizophrenia, 17(4):565-582, 1991.
- Mueser, K.T.; Yarnold, P.R.; Levinson, D.F.; Singh, H.; Bellack, A.S.; Kee, K.; Morrison, R.L.; and Yadalam, K.G. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates, 16(1):31-56, 1990.
- N**
- Nasrallah, H.A.; Schwarzkopf, S.B.; Olson, S.C.; and Coffman, J.A. Gender differences in schizophrenia on MRI brain scans, 16(2):205-210, 1990.
- Nelson, J.C.; *see* Bowers, M.B., Jr.
- Neri, L.; *see* Moscarelli, M.
- Nicol, S.; *see* Vinogradov, S.
- Nienhuis, F.J.; *see* Wiersma, D.
- Noordsy, D.L.; *see* Drake, R.E.
- O**
- Olson, S.C.; *see* Nasrallah, H.A.
- Osher, F.C.; *see* Drake, R.E.
- Ott, J.; *see* Weeks, D.E.
- P**
- Paige, S.R.; *see* Karson, C.N.
- Paredes, J.; *see* Koczapski, A.B.
- Pfefferbaum, A.; Lim, K.O.; Rosenbloom, M.; and Zipursky, R.B. Brain magnetic resonance imaging: Approaches for investigating schizophrenia, 16(3):453-476, 1990.

Plasky, P. Antidepressant usage in schizophrenia, 17(4):649-657, 1991.

Potkin, S.G.; see Jin, Y.

Pulver, A.E.; Moorman, C.C.; Brown, C.H.; McGrath, J.A.; and Wolyniec, P.S. Age-incidence artifacts do not account for the season-of-birth effect in schizophrenia, 16(1):13-15, 1990.

R

Rafferty, J.; see Burns, T.

Raine, A. The SPQ: A scale for the assessment of schizotypal personality based on *DSM-III-R* criteria, 17(4):555-564, 1991.

Rasmussen, M.; see Harvey, P.D.

Rice, D.; see Jin, Y.

Ridgely, M.S.; Goldman, H.H.; and Willenbring, M. Barriers to the care of persons with dual diagnoses: Organizational and financing issues, 16(1):123-132, 1990.

Riger, S.; see Holmes-Eber, P.

Risch, S.C.; see Lewine, R.R.J.

Robbins, T.W. The case for frontostriatal dysfunction in schizophrenia, 16(3):391-402, 1990.

Roemer, R.A.; see Josiassen, R.C.

Rogers, J.A., and Centifanti, J.B. Beyond "self-paternalism": Response to Rosenson and Kasten, 17(1):9-14, 1991.

Rosenbloom, M.; see Pfefferbaum, A.

Rosenson, M.K., and Kasten, A.M. Another view of autonomy: Arranging for consent in advance, 17(1):1-7, 1991.

Rotov, M. Phenomenology or physicalism?, 17(2):183-186, 1991.

Ruocchio, P.J. First person account: The schizophrenic inside, 17(2):357-360, 1991.

Rüphan, M.; see Wiersma, D.

Rupp, A. Underinsurance for severe mental illness, 17(3):401-405, 1991.

S

Safferman, A.; Lieberman, J.A.;

Kane, J.M.; Szymanski, S.; and Kinon, B. Update on the clinical efficacy and side effects of clozapine, 17(2):247-261, 1991.

Sandman, C.A.; see Jin, Y.

Sandyk, R., and Kay, S.R. Pineal melatonin in schizophrenia: A review and hypothesis, 16(4):653-662, 1990.

Santangelo, S.L.; see Goldstein, J.M.

Sartorius, N., and de Girolamo, G. Preface, 17(3):371-373, 1991.

Saugstad, L.F. Social class, marriage, and fertility in schizophrenia: The author replies, 16(2):175-178, 1990.

Saykin, A.J.; see Gur, R.E.

Scherillo, P.; see Battaglia, M.

Schooler, N.R. Maintenance medication for schizophrenia: Strategies for dose reduction, 17(2):311-324, 1991.

Schöttner, B.; see Wiedl, K.H.

Schwarzkopf, S.B.; see Nasrallah, H.A.

Sciuto, G.; see Battaglia, M.

Seeman, M.V., and Lang, M. The role of estrogens in schizophrenia gender differences, 16(2):185-194, 1990.

Selzer, J.; see Kane, J.M.

Serper, M.R.; see Harvey, P.D.

Sevy, S.; see Kay, S.R.

Shagass, C.; see Josiassen, R.C.

Sharfstein, S.S. Prospective cost allocations for the chronic schizophrenic patient, 17(3):395-400, 1991.

Silverstein, M.L.; Marengo, J.T.; and Fogg, L. Two types of thought disorder and lateralized neuropsychological dysfunction, 17(4):679-687, 1991.

Simpson, J.C.; see Goldstein, J.M.

Singer-Sam, J. An epigenetic role in schizophrenia (Letter to the Editor), 17(3):365, 1991.

Singh, B.S.; see McGorry, P.D.

Siris, S.G. Diagnosis of secondary

depression in schizophrenia: Implications for *DSM-IV*, 17(1):75-98, 1991; Pharmacological treatment of substance-abusing schizophrenic patients, 16(1):111-122, 1990.

Smith, E. First person account: Living with schizophrenia, 17(4):689-691, 1991.

Sorensen, I.; see Benes, F.M.

Spencer, J.H.; see Haas, G.L.

Squires-Wheeler, E.; see Weeks, D.E.

Sramek, J.; see Jin, Y.

Stefanovich, M.; see Weeks, D.E.

Strauss, D.H.; see Amador, X.F.

Struening, E.L.; see Susser E.S.

Stuss, D.T.; see Benson, D.F.

Susser, E.S., and Struening, E.L. Diagnosis and screening for psychotic disorders in a study of the homeless, 16(1):133-145, 1990.

Sweeney, J.; see Dixon, L.

Szymanski, S.; see Safferman, A.

Szymanski, S.; Kane, J.M.; and Lieberman, J.A. A selective review of biological markers in schizophrenia, 17(1):99-111, 1991.

T

Teague, G.B.; see Drake, R.E.

Test, M.A.; Burke, S.S.; and Wallich, L.S. Gender differences of young adults with schizophrenic disorders in community care, 16(2):331-344, 1990.

Torrey, E.F. A viral-anatomical explanation of schizophrenia, 17(1):15-18, 1991.

Torrey, E.F., and Bowler, A. Geographical distribution of insanity in America: Evidence for an urban factor, 16(4):591-604, 1990.

Torrey, E.F., and Bowler, A.E. The seasonality of schizophrenic births: A reply to Marc S. Lewis, 16(1):1-3, 1990.

Tsuang, M.T.; see Goldstein, J.M.;

Turner, W.M.

Turner, W.M., and Tsuang, M.T. Impact of substance abuse on the

course and outcome of schizophrenia, 16(1):87-95, 1990.

V

- Van Putten, T.; Marder, S.R.; Wirshing, W.C.; Aravagiri, M.; and Chabert, N. Neuroleptic plasma levels, 17(2):197-216, 1991.
 van Riel, R.J.; *see* McGorry, P.D.
 Vinogradov, S.; Gottesman, I.I.; Moises, H.W.; and Nicol, S. Negative association between schizophrenia and rheumatoid arthritis, 17(4):669-678, 1991.

W

- Wagman, A.M.I.; *see* Kirch, D.G.
 Waldo, M.C.; *see* Adler, L.E.
 Wallach, M.A.; *see* Bartels, S.J.
 Wallisch, L.S.; *see* Test, M.A.
 Watson, C.G. Schizophrenic birth seasonality and the age-incidence

artifact, 16(1):5-10, 1990.

- Weeks, D.E.; Brzustowicz, L.; Squires-Wheeler, E.; Cornblatt, B.; Lehner, T.; Stefanovich, M.; Bassett, A.; Gilliam, T.C.; Ott, J.; and Erlenmeyer-Kimling, L. Report of a workshop on genetic linkage studies in schizophrenia, 16(4):673-686, 1990.
 Weiden, P.; *see* Dixon, L.
 Wethington, E.; *see* Lenzenweger, M.F.
 Wiedl, K.H., and Schöttner, B. Coping with symptoms related to schizophrenia, 17(3):525-538, 1991.
 Wiersma, D.; Kluiter, H.; Nienhuis, F.J.; Rüphan, M.; and Giel, R. Costs and benefits of day treatment with community care for schizophrenic patients, 17(3):411-419, 1991.

- Willenbring, M.; *see* Ridgely, M.S.
 Wirshing, W.C.; *see* Van Putten, T.
 Witelson, S.F., and McCulloch, P.B. Premortem and postmortem measurement to study structure with function: A human brain collection, 17(4):583-591, 1991.
 Wolyniec, P.S.; *see* Pulver, A.E.
 Wood, F.B., and Flowers, D.L. Hypofrontal vs. hypo-Sylvian blood flow in schizophrenia, 16(3):413-424, 1990.
 Wyatt, R.J. Neuroleptics and the natural course of schizophrenia, 17(2):325-351, 1991. *see also* Christison, G.W.

Y

- Yadalam, K.G.; *see* Mueser, K.T.
 Yale, S.A.; *see* Amador, X.F.
 Yarnold, P.R.; *see* Mueser, K.T.

Z

- Zipursky, R.B.; *see* Pfefferbaum, A.

Subject Index

A

- Age factors**
 Age-incidence effect clarification, 16:13
 Age of onset and gender differences, 16:211
 Seasonality and age-incidence effect, 16:1, 16:5, 16:11, 16:17
Alcohol. *See also* Substance abuse comorbidity
 Alcohol use disorders assessment instrument is needed, 16:57
Antihistamines
 Intoxication-related behavior patterns, 16:373
Antipsychotic drugs. *See* Neuroleptics; Treatment
Auditory hallucinations
 Relationship to subvocal activity, 16:617

- Auditory sensory gating**
 Hippocampal abnormality and auditory sensory gating, 17:19
Autobiographical accounts. *See also* Subjective experiences
 Coping strategies, 16:547
 Course of illness description, 16:165
 Inside view of illness, 17:357
 Mother's view of daughter's illness, 17:689
 Mother's view of son's illness, 16:687, 17:539
 Psychotic episode and hospitalization, 16:355
 Treatment of the chronically mentally ill, 17:173

B

- Behavior**
 Caffeine sensitivity, 16:371
 Hostility variables identified, 17:163

- Intoxication-related behavior patterns, 16:373
- Neurobehavioral studies of frontal and temporal lobe dysfunction, 16:445
- Biological markers**
- Studies needed to develop trait markers, 17:99
- Biological psychiatry**
- Criticism of the underlying assumptions, 17:183
- Brain areas**
- Frontal lobes, basal ganglia, and temporal lobes, 16:377, 16:379
- Frontal lobe influences on delusions, 16:403
- Posterior hippocampus neuronal size, 17:597
- Right- and left-hemisphere neuropsychological dysfunction, 17:679
- Brain development**
- Age of onset and gender differences relation to, 16:211
- Computer model of cortical pruning, 16:567
- Fetal asymmetries, 17:551
- Neurodevelopmental model of schizophrenia and manic depressive illness, 16:171, 16:175
- Temporal lobe asymmetries, 16:433
- Brain imaging**
- Frontal and temporal lobe dysfunction, 16:445
- Frontal lobe influences on delusions, 16:403
- Frontal lobes, basal ganglia, and temporal lobes, 16:377
- Frontostriatal dysfunction hypothesis of schizophrenia, 16:391
- Gender differences in regional cerebral blood flow, 16:247
- Hypofrontality and hypo-Sylvian blood flow, 16:413
- Magnetic resonance imaging, 16:205, 16:453
- Photic stimulation responses and EEG spectra, 16:627
- Positron emission tomography studies, 16:379
- Temporal lobe asymmetries, 16:433
- Brain morphology**
- Brain tissue collection issues, 17:593
- Sex differences and neuropsychological performance, 16:195
- Structure-function relationship postmortem studies, 17:583
- C**
- Caffeine**
- Caffeine sensitivity and psychotogenic actions, 16:371
- Intoxication-related behavior patterns, 16:373
- Classification**
- American-Soviet systems, 17:553
- DSM-III-R* and ICD-10 definition comparison, 17:27
- Five criteria sets for *DSM-IV* field trials, 17:143
- Introduction to *DSM-IV* proposed changes, 17:25
- Role of prodromal and residual symptoms, duration of psychotic symptoms, and the 6-month vs. 1-month criterion, 17:51
- Subtype criteria for *DSM-IV*, 17:609
- Cognition**
- Manic and schizophrenic patient followup study, 16:147
- Community Adjustment Scale**, 16:309
- Comorbidity**. *See* Substance abuse comorbidity
- Coping strategies**
- Assessment method, 17:525
- Autobiographical account, 16:547
- Course and outcome**. *See* Long-term followup studies
- Cranial size**
- Relation to schizotypal personality disorder and schizophrenia, 17:157
- D**
- Delusions**
- Frontal lobe influences, 16:403
- Review of research and theoretical work, 17:633
- Deodorants and aerosols**
- Intoxication-related behavior patterns, 16:373
- Depression**
- Comorbidity and suicide risk, 16:571
- Relevance of secondary depression, 17:75
- Seasonality issues, 17:191
- Tricyclic antidepressant treatment, 17:649
- Diagnosis**. *See also* Classification
- Alcohol use disorders assessment instrument is needed, 16:57
- Alternative diagnostic criteria and field trial modifications, methods, and goals, 17:133
- American-Soviet classification systems, 17:553
- Biological markers identified, 17:99
- Criteria sets for *DSM-IV* field trials, 17:143
- Historical concepts of "characteristic symptoms," 17:27
- Introduction to *DSM-IV* proposed changes, 17:25
- National Plan for Schizophrenia Research, 17:183
- Organic factor exclusion criteria issues, 17:69
- Role of prodromal and residual symptoms, duration of psychotic symptoms, and the 6-month vs. 1-month criterion, 17:51
- Subtype criteria, 17:609
- Diagnostic and Statistical Manual**
- Criteria sets for *DSM-IV* field trials, 17:143

DSM-III-R and ICD-10 definition comparison, 17:27

Introduction to proposed changes in diagnostic criteria, 17:25

Subtype criteria for *DSM-IV*, 17:609

Dopamine

Dopaminergic activity and atypical antipsychotic drugs, 17:263

Dopaminergic hyperactivity, 16:605

Glutamate-dopamine imbalance, 16:425

E

Economic factors

Assessment procedures to evaluate costs, 17:475

Budgeting costs of treatment for chronic patients, 17:395

Community-based treatment, case-management approaches, and capitation funding, 17:461

Community care and hospitalization cost-effectiveness comparison, 17:453

Community care cost-effectiveness evaluation, 17:441

Cost of mental illness and schizophrenia for 1955 and 1985, 17:367

Cost variables and outcome, 17:427

Costs associated with improper measurement and unreliability, 17:483

Day treatment costs and benefits, 17:411

Home-based and standard care comparison, 17:407

Incidence-based costing algorithm, 17:389

Overview of cost of illness, 17:367

Prediction of service utilization and cost, 17:469

Three-year costs of chronic schizophrenic patients, 17:421

Uninsurance and underinsurance issues, 17:401

Environmental factors

Migrant studies and environmental factor determination, 16:663

Epidemiology

Negative association between rheumatoid arthritis and schizophrenia, 17:669

Season of birth, 16:1, 16:5, 16:11, 16:13, 16:17

Secondary depression occurrence, 17:75

Substance abuse comorbidity, 16:29, 16:31

Urban factor of geographical distribution of insanity, 16:591

Etiology. See also Diagnosis

Auditory sensory gating and hippocampal structure abnormality, 17:19

Family history positive vs. family history negative, 16:367

Frontostriatal dysfunction hypothesis, 16:391

Neurotransmitter imbalance, 16:425

Organic factor exclusion criteria issues, 17:69

Temporal lobe asymmetries, 16:433

Viral infections and schizophrenia, 17:15

Event-related brain potentials

Influences of gender on, 16:229

F

Families

Cranial size relation to schizotypal personality disorder and schizophrenia in siblings, 17:157

Family history positive vs. family history negative, 16:367

Family response to inpatient family intervention, 16:277

Gender differences in risk and development of schizophrenia, 16:263

Genetic linkage studies, 17:491

Morbidity risk for schizophrenia in schizotypal patients, 17:659

G

Gender differences

Age of onset and gender differences in relation to brain development, 16:211

Clinical profiles and long-term outcomes in Chestnut Lodge study participants, 16:319

Course and outcome studies, 16:293

Estrogen role, 16:185

Influences of gender on event-related brain potentials, 16:229

Introduction and synthesis of findings, 16:179

MRI study of cerebral structures, 16:205

Olfactory agnosia, 16:255

Premorbid social functioning, gender, and long-term outcome relationships, 16:309

Regional cerebral blood flow studies, 16:247

Risk differences for developing different subtypes of schizophrenia, 16:263

Role functioning differences, 16:277

Suicide risk, 16:571

Young adults in progressive community care, 16:331

Genetic factors

Diminished melatonin secretion as marker, 16:653

Epigenetic role, 17:365

Familial/sporadic subdivision use as clinical research method, 16:363

Genetic linkage studies, 17:491

Genetic linkage studies workshop report, 16:673

Hippocampal abnormality and auditory sensory gating, 17:19

Temporal lobe asymmetries, 16:433

Glutamate

Role in control of psychomotor activity, 16:425

Grants

- Schizophrenia-related grants, fiscal year 1989, 16:691
- Schizophrenia-related grants, fiscal year 1990, 17:693

H**Homeless persons**

- Screening scales for psychotic symptoms, 16:133

Hormones

- Estrogen role in gender differences, 16:185

Hospitalization

- Effect on social network size and composition, 16:157
- "Hostel ward" alternative, 17:453

Hostility

- Six variables identified, 17:163

Hyperventilation

- Intoxication-related behavior patterns, 16:373

Hypofrontality

- Hypo-Sylvian blood flow comparison, 16:413

I**Insurance**

- Uninsurance and underinsurance issues, 17:401

International Classification of Diseases

- DSM-III-R and ICD-10 definition comparison, 17:27

L**Legal issues**

- Prior consent agreements and patient's right to refuse treatment, 17:1, 17:9

Long-term followup studies

- Community-based treatment, case-management approaches, and capitation funding, 17:461
- Community care and hospitalization cost-effectiveness evaluation, 17:453
- Cost variables and outcome, 17:427

- Day treatment costs and benefits, 17:411

Gender differences in Chestnut

- Lodge study participants, 16:319

- Gender differences in course and outcome, 16:293

- Gender differences in young adults study of progressive community care, 16:331

- Manic and schizophrenic patient followup, 16:147

- Neuroleptics and natural course of schizophrenia, 17:325

- Premorbid social functioning, gender, and long-term outcome relationships, 16:309

- Substance abuse impact on course and outcome, 16:87

M**Magnetic resonance imaging**

- Frontal lobes, temporal lobes, and basal ganglia, 16:453
- Gender differences, 16:205

Migrant studies

- Role in environmental factor determination, 16:663

Molecular biology

- Negative association between rheumatoid arthritis and schizophrenia, 17:669

N**National Plan for Schizophrenia Research**

- Clinical phenomenology, 17:183

Negative syndromes

- Measurement and assessment, 16:635

Neuroleptics

- Clozapine efficacy and side effects, 17:247
- Effects on neuropsychological function in chronic cases, 16:477
- Natural course of schizophrenia studies, 17:325
- Plasma level variations, 17:197
- Psychotogenic drug use effect on neuroleptic response, 16:81

- Treatment alternatives for neuroleptic-resistant patients, 17:217

- Tricyclic antidepressants used with neuroleptics for depression treatment, 17:649

Neuropathology

- Blink-alpha neurocircuit, 16:345

Neuropsychology

- Effects of neuroleptics on neuropsychological function in chronic cases, 16:477
- Sex differences in brain morphology and neuropsychological performance, 16:195

Neurotransmitters

- Dopamine-glutamate imbalance, 16:425

Nicotine

- Intoxication-related behavior patterns, 16:373

O**Olfactory agnosia, 16:255****Organic factor**

- Exclusion criteria issues, 17:69

Outcome. See Long-term followup studies**P****Patient rights**

- Prior consent agreements and patient's right to refuse treatment, 17:1, 17:9

Phenomenology

- Criticism of the underlying assumptions of "Biological Psychiatry," 17:183
- History of the term, 17:187
- Three-process model for structure of schizophrenic phenomenology, 17:515

Pineal gland

- Diminished melatonin secretion as marker, 16:653

Positive syndromes

Measurement and assessment,
16:635

Positron emission tomography

Frontal lobe, basal ganglia, and
temporal lobe studies, 16:379

Premorbid Adjustment Scale, 16:309

Prognosis. *See* Long-term followup
studies

Psychiatric Epidemiology Research

Instrument, 16:133

Psychomotor activity

Glutamate role, 16:425

R**Research design and methodology**

Age incidence can be a source of
error, 16:11

Brain structure-function relation-
ship postmortem studies, 17:583

Brain tissue collection issues,
17:593

Clarification of age-incidence ef-
fect, 16:13

Community care cost-effectiveness
evaluation, 17:441

Cost variables and outcome, 17:427

Delusions, 17:633

Dose reduction methods review,
17:311

Familial/sporadic subdivisions,
16:363

Field trials of diagnostic criteria,
17:133

Genetic linkage studies, 17:491

Incidence-based costing algorithm,
17:389

Methodological issues in assessing
prevalence of substance abuse
comorbidity, 16:31

Migrant studies and environmental
factor determination, 16:663

Neurodevelopmental model of
schizophrenia and manic depres-
sive illness, 16:171, 16:175

Obstacles to treatment research,
17:353

Organic factor exclusion criteria
issues, 17:69

Positive and negative syndrome
research, 16:635

Prediction of service utilization
and cost, 17:469

Quantitative morphometric tech-
niques to study posterior hippo-
campus neuronal size, 17:597

Screening for psychotic symptoms
in community studies, 16:133

Seasonality and age-incidence ef-
fect, 16:17

Seasonality result of design prob-
lems or age-incidence effect, 16:5

Substance abuse impact on course
and outcome design and method
suggestions, 16:87

Three-process model for structure
of schizophrenic phenomenol-
ogy, 17:515

Rheumatoid arthritis

Negative association between rheu-
matoid arthritis and schizo-
phrenia, 17:669

**Royal Park Multidiagnostic Instru-
ment for Psychosis**

Development and structure, 16:517

Rationale and review, 16:501

S**Scales**

Assessment method for coping
strategies, 17:525

Community Adjustment Scale,
16:309

Premorbid Adjustment Scale,
16:309

Psychiatric symptom scale suggests
pyramidal model, 16:537

Quality of Life Scale, 17:565

Royal Park Multidiagnostic Instru-
ment for Psychosis, 16:501,
16:517

Scale for the Assessment of Nega-
tive Symptoms, 17:565

Schedule for Schizotypal Personali-

ties interview, 17:157

Schizotypal Personality Question-
naire, 17:555

Screening for psychotic symptoms
in community studies, 16:133

**Schedule for Schizotypal Personali-
ties interview, 17:157**

Schizoaffective disorder

Clinical profiles and long-term out-
comes in Chestnut Lodge study
participants, 16:319

Schizotypal personality disorder

Assessment scale, 17:555

Cranial size relationship, 17:157
Morbidity risk for schizophrenia,
17:659

**Schizotypal Personality Question-
naire, 17:555**

Season of birth

Age incidence in season-of-birth
studies, 16:11

Clarification of age-incidence ef-
fect, 16:13

Seasonality and age-incidence ef-
fect, 16:1, 16:17

Seasonality of schizophrenia and
of depressive episodes, 17:191

Seasonality result of design prob-
lems or age-incidence effect, 16:5

Self-awareness deficits. *See* Unaware-
ness of illness

Social functioning

Premorbid social functioning, gen-
der, and long-term outcome re-
lationships, 16:309

Social networks

Effect of hospitalization on network
size and composition, 16:157

Socioeconomic factors

Regional correlation of schizo-
phrenia with, 16:591

Statistical issues. *See also* Research
design and methodology

Reliability, measurements, and
costs, 17:483

Season-of-birth studies, 16:1, 16:5,
16:11, 16:13, 16:17

Stimulants

- Impact of stimulant use on schizophrenia, 16:97

Structured Clinical Interview for DSM-III-R: Psychotic Disorders,
16:133

Subjective experiences

- Acute intoxication, 16:69

Substance abuse comorbidity

- Acute intoxication, 16:69
- Alcohol use disorders are common comorbid conditions, 16:57
- Editors' overview, 16:29
- Methodological issues in assessing prevalence, 16:31
- Organizing and financing care of patients with comorbidities, 16:123
- Pharmacological treatment, 16:111
- Psychotogenic drug use effect on neuroleptic response, 16:81
- Stimulant abuse, 16:97

Suicide

- Risk factor review, 16:571

Symptoms

- Enduring negative and deficit symptoms, 17:565
- Historical concepts of "characteristic symptoms," 17:27
- Role of prodromal and residual symptoms, duration of psychotic symptoms, and the 6-month vs. 1-month criterion, 17:51
- Secondary depression, 17:75

T**Tardive dyskinesia**

- Dose reduction issues, 17:311

Thought disorder

- Manic and schizophrenic patient

- followup study, 16:147

- Right- and left-hemisphere neuropsychological dysfunction, 17:679

Treatment

- Action of atypical antipsychotic drugs, 17:263
- Antipsychotics reviewed for efficacy and adverse effects, 17:289
- Behavioral interventions for auditory hallucinations, 16:617
- Budgeting costs of treatment for chronic patients, 17:395
- Clozapine clinical efficacy and side effects, 17:247
- Community-based treatment, case-management approaches, and capitation funding, 17:461
- Community care and hospitalization cost-effectiveness evaluation, 17:453
- Community care cost-effectiveness evaluation, 17:441
- Cost of mental illness and schizophrenia for 1955 and 1985, 17:367
- Day treatment costs and benefits, 17:411
- Defining refractoriness, 16:551, 16:563
- Dose reduction and tardive dyskinesia risk, 17:311
- Effects of neuroleptics on neuropsychological function in chronic cases, 16:477
- Home-based and standard care comparison, 17:407
- Inpatient family intervention, 16:277
- Neuroleptic plasma level variations in patients, 17:197

Neuroleptic-resistant patient alternatives, 17:217

- Neuroleptics and natural course of schizophrenia studies, 17:325
- Organizing and financing care of patients with comorbidities, 16:123
- Overview of pharmacological treatments, 17:193
- Pharmacological treatment of substance abuse, 16:111
- Prior consent agreements and patient's right to refuse the treatment, 17:1, 17:9
- Research and new drug development obstacles, 17:353
- Secondary depression, 17:75
- Tricyclic antidepressant treatment for depression, 17:649
- Uninsurance and underinsurance issues, 17:401

U**Unawareness of illness**

- Review of literature and assessment guidelines, 17:113

Unipolar affective disorder

- Clinical profiles and long-term outcomes in Chestnut Lodge study participants, 16:319

Urbanization

- Regional correlation of insanity/schizophrenia with, 16:591

V**Viral infections**

- Viruses in cranial cavity may cause schizophrenia symptoms, 17:15

W**Water**

- Intoxication-related behavior patterns, 16:373